尽管最近有所改善,但非小细胞肺癌(NSCLC)的5年生存率仍然很低(<21%)。因为传统疗法有很多副作用,强烈建议联合治疗。这里,我们报告了一名接受联合治疗的晚期非小细胞肺癌患者,包括ceritinib,光生物调节(PBM),ACGL(牛樟芝(A.肉桂),和灵芝(G.lucidum)).在综合治疗的基础上,适宜剂量的肉桂,G.lucidum,和PBM对于肿瘤抑制是重要的。该病例报告提供了晚期NSCLC患者联合治疗疗效的临床证据。包括计算机断层扫描(CT)扫描,磁共振成像(MRI),癌胚抗原(CEA),和血液测试。证明了对人肺腺癌细胞的有效抑制。我们的案例强调了在NSCLC患者中PBM和ACGL应用的重要考虑因素,色瑞替尼的副作用,和长期的健康维护。
The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including ceritinib, photobiomodulation (PBM), ACGL (Antrodia cinnamomea (A. cinnamomea), and Ganoderma lucidum (G. lucidum)). Based on combined therapy, suitable doses of A. cinnamomea, G. lucidum, and PBM are important for tumor inhibition. This
case report presents clinical evidence on the efficacy of combined therapy in advanced NSCLC patients, including computed tomography (CT) scan, magnetic resonance imaging (MRI), carcinoembryonic antigen (CEA), and blood tests. The effective inhibition of human lung adenocarcinoma cells is demonstrated. Our
case highlights important considerations for PBM and ACGL applications in NSCLC patients, the side effects of ceritinib, and long-term health maintenance.